Any improvement that is recognised by the company is good news for me, for me if i have 3 easily read, exciting investment docs and one poorly scanned 4th generation black and white , i know which ones i favour, Biotechs now realise the data has to be easily digestible by the general investment public as well as the technical industry boffins...
so i look forward to the next announcement to see the level of copy to have risen as well as clear concise diagrams...
Ann: CMO Appointment and Clinical Trials Update, page-127
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.025(6.67%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.0¢ | $387.8K | 1.079M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 394907 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 15948 | 1 |
View Market Depth
| Last trade - 16.10pm 12/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |